Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies

Published:2018-05-16 Issue:9 Volume:25 Page:1066-1077
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Wisløff T.¹²^ORCID,White R.¹,Dalgard O.³⁴,Amundsen E. J.⁵,Meijerink H.¹,Kløvstad H.⁶

Affiliation:

1. Department of Infectious Disease Epidemiology and Modelling; Norwegian Institute of Public Health; Oslo Norway

2. Department of Health Management and Health Economics; University of Oslo; Oslo Norway

3. Department of Infectious Diseases; Akershus University Hospital; Lørenskog Norway

4. Division of Medicine and Laboratory Sciences; University of Oslo; Oslo Norway

5. Department of Alcohol, Tobacco and Drugs; Norwegian Institute of Public Health; Oslo Norway

6. Department of Tuberculosis, Blood Borne and Sexually Transmitted Infections; Norwegian Institute of Public Health; Oslo Norway

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12904/fullpdf

Reference50 articles.

1. Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030;Meijerink;BMC Infect Dis,2017

2. Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals;Chhatwal;Pharmacoeconomics,2016

3. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios;Harris;J Hepatol,2014

4. Cost-effectiveness of new antiviral regimens for treatment-naive U.S. veterans with hepatitis C;Chidi;Hepatology,2016

5. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation;Martin;J Hepatol,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway;Scandinavian Journal of Gastroenterology;2022-09-05

2. A Systematic Review of Simulation Models to Track and Address the Opioid Crisis;Epidemiologic Reviews;2021

3. HIPPOCRATES® project: A proof of concept of a collaborative program for hepatitis C virus micro-elimination in a prison setting;World Journal of Hepatology;2020-12-27

4. Prescribing direct‐acting antivirals to treat hepatitis C virus in a general practice setting in Australia: ‘so why not do it’?;Internal Medicine Journal;2020-09

5. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units;International Journal of Drug Policy;2019-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3